Satellos files phase 2 trial submissions for SAT-3247

Executive Summary

• Satellos Bioscience Inc. has submitted an Investigational New Drug (IND) application to the U.S. FDA, along with parallel regulatory filings in the UK, Europe, Serbia, and Australia, to initiate a Phase 2 clinical trial of SAT-3247.
• The Phase 2 trial is designed to assess the safety, tolerability, and efficacy of SAT-3247 in ambulatory children with Duchenne Muscular Dystrophy (DMD), including measures of strength, function, biomarkers, and muscle health.
• The company reported recent corporate updates regarding the exercise of warrants and the expiration of remaining warrants from a previous financing round.

Key Details

• Regulatory Filings: Submission of IND to the U.S. FDA; parallel filings in the United Kingdom, Europe, Serbia, and Australia.
• Phase 2 Trial Design:
  • Population: Ambulatory children with Duchenne Muscular Dystrophy (DMD).
  • Study Type: Three-month randomized, placebo-controlled study.
  • Objectives: Assess safety, tolerability, strength, function, biomarkers, and muscle health.
  • Extension: A nine-month open-label extension is planned.
  • Geography: Enrollment in the U.S. (pending FDA approval) and globally (pending country health authority approvals).
• SAT-3247 Mechanism: Oral small-molecule therapy targeting AAK1 to restore muscle regeneration by replacing the signal normally provided by dystrophin in muscle stem cells.
• Phase 1b Results (Adults):
  • Safety: Safe and well-tolerated; pharmacokinetics mirrored healthy volunteers.
  • Efficacy Signals: Approximate doubling of grip strength observed over 28 days; 5% improvement in force vital capacity (lung function).
• Ongoing Studies: An 11-month extension study is currently underway in Australia to evaluate long-term safety and efficacy among Phase 1b participants, with further expansions planned.
• Corporate/Financial Update:
  • Warrant Exercises: 1,737,500 share purchase warrants were exercised for gross proceeds of $1,042,500.
  • Previous Exercises: 911,000 warrants had been previously exercised (as per Q2 2025 financials).
  • Expiration: 1,726,500 warrants expired on Sept. 13, 2025.
  • Original Financing: Aggregate of 4,375,000 warrants were issued pursuant to a financing that closed on Sept. 13, 2022.

Notable Quotes

• "Filing our phase 2 clinical trial submissions in the U.S. and globally marks a major milestone for Satellos in advancing SAT-3247's potential to treat Duchenne in a novel way," said Satellos co-founder and chief executive officer Frank Gleeson. "Current therapies do not address the fundamental challenge in Duchenne, which we have identified -- the body's impaired muscle-repair process. With SAT-3247, our goal is to reboot that regenerative cycle with the potential to restore muscle, improve functional outcomes and truly change lives."